UTRAP
Live / Applied — Third extension granted (statement of use) (as of 20 Feb 2026)
What this means for you
Not registered yet, but its 06 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98166206
- Mark type
- Stylized text
- Filed
- 06 Sept 2023
- Published for opposition
- 25 Jun 2024
- Attorney of record
- Adriano Pacifici
Goods and services
- Class 001 — Chemicals: Lipid nanoparticles for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing surface chemistry for attachment of any protein, peptide and molecule to bind proteins of interest for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, and metabolic disorders; Biochemical preparations for scientific medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders; Reagents for scientific research and medical research use; Chemical reagents for non-medical purposes; Diagnostic reagents for clinical or medical laboratory use; chemistry reagents for scientific research and medical research use; Reagents comprised of nanoparticles for scientific research and medical research use; Reagents comprised of capsids for scientific research and medical research use; Reagents, namely, lipid nanoparticles, for scientific research and medical research use
- Class 005 — Pharmaceuticals: Pharmaceutical products, namely, lipid nanoparticles, for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases, namely, a lipid-enabled drug for binding to agents of interest in particular viruses, bacteria, free-circulating proteins in the body; Pharmaceutical agents for treating respiratory diseases in the nature of biological blocking agents in the form of lipid nanoparticles that facilitate the binding of viruses, bacteria, protein of interest in biological fluids; Pharmaceutical preparations for the treatment of diseases and disorders, namely, allergies, autoimmune diseases, cancer, cardiovascular diseases, genetic diseases, hematological diseases, infectious diseases, inflammatory diseases, metabolic diseases, neurological diseases, ocular diseases and respiratory diseases
Owner
- utR Biotech, Winnipeg, MB, CA
- utR Biotech, Winnipeg, MB, CA
Prosecution history
- 20 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Feb 2026 — SOU EXTENSION 3 GRANTED
- 20 Feb 2026 — SOU EXTENSION 3 FILED
- 20 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 21 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Aug 2025 — SOU EXTENSION 2 GRANTED
- 20 Aug 2025 — SOU EXTENSION 2 FILED
- 20 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Feb 2025 — SOU EXTENSION 1 GRANTED
- 19 Feb 2025 — SOU EXTENSION 1 FILED
- 19 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Jun 2024 — PUBLISHED FOR OPPOSITION